Recent Updates
Recently added Catalysts

Adaptimmune Therapeutics PLC Sponsored ADR

ADAP
Biotech · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$0.05
▼ -0.01 · -17.57%

Last traded Oct 27, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ADAP financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.0452W HIGH $0.86
Volume
50.78 M
Value Traded
3.17 M
Short % Float
2%
-19.32%Week
-58.72%1 Month
-54.25%3 Month
-78.87%6 Month
-98.85%5 Year
-99.71%All Time

Cash Data

Unlock ADAP cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
17.15 M
EPS (TTM)
-0.66
P/E Ratio
-
Ent. Value
39.77 M
Total Shares
265.05 M
Float Shares
255.41 M
Insiders
11.33%
Institutions
34.07%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every ADAP catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ADAP Catalyst Timeline

Dated clinical, regulatory and corporate events for Adaptimmune Therapeutics PLC Sponsored ADR

Unlock the full ADAP catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ADAP actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-12-31lete-cel BLA Submission BLA
Unlock 4 more ADAP historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D32 / 100
Pipeline Score
$10M
Pipeline Value
Not rated
Valuation Signal
5
Drugs Scored
-
rNPV / MCap
Adaptimmune Therapeutics PLC Sponsored ADR faces pipeline headwinds (32/100), with $821M risk-adjusted pipeline value, led by Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T in Non-Small Cell Lung Cancer (Phase 1).
Showing 1 of 5 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T Monoclonal antibodyCompletedNCT02592577Non-Small Cell Lung CancerPhase 1 COMPLETED 28Mar 17, 2021
Unlock the ADAP pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ADAP program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
lete-cel advanced or metastatic synovial sarcoma or MRCLSPhase 22024-11-13overall response rate: 42%; complete responses: 6/64; partial responses: 21/64; response rate synovial sarcoma: 41%; response rate MRCLS: 43%; median duration of response: 12.2 months; median duration of response synovial sarcoma: 18.3 monthsRead MoreAdaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial 42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); twRead More
Scroll for more · summaries link to the source press release
Unlock every ADAP trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ADAP insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Wood GavinOfficer (Chief Financial Officer)Sell -96,000 $0.01 09/02/2025
Unlock the full ADAP insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in ADAP

Fund % of Portfolio Current MV Shares Owned Activity
EcoR1 Capital, LLC 0.4 % (33.3 %) 6.57 M 27.40 M
Unlock every fund holding ADAP
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ADAP
Shares held by hedge funds each quarter, and who bought or sold.

ADAP Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock ADAP option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ADAP option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ADAP options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ADAP ranks across every disease it competes in

Competitive Position is a premium feature
See how ADAP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ADAP News

About Adaptimmune Therapeutics PLC Sponsored ADR

Founded06-05-2015
BIOPHARMAWATCH ELITE PLUS
Trade the next ADAP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime